| Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice PK Dash, R Kaminski, R Bella, H Su, S Mathews, TM Ahooyi, C Chen, ... Nature communications 10 (1), 1-20, 2019 | 289 | 2019 |
| Creation of a long-acting nanoformulated dolutegravir B Sillman, AN Bade, PK Dash, B Bhargavan, T Kocher, S Mathews, H Su, ... Nature communications 9 (1), 443, 2018 | 110 | 2018 |
| A year-long extended release nanoformulated cabotegravir prodrug TA Kulkarni, AN Bade, B Sillman, BLD Shetty, MS Wojtkiewicz, N Gautam, ... Nature materials 19 (8), 910-920, 2020 | 81 | 2020 |
| Long-acting slow effective release antiretroviral therapy B Edagwa, JE McMillan, B Sillman, HE Gendelman Expert opinion on drug delivery 14 (11), 1281-1291, 2017 | 77 | 2017 |
| Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs DP Gnanadhas, PK Dash, B Sillman, AN Bade, Z Lin, DL Palandri, ... The Journal of clinical investigation 127 (3), 857-873, 2017 | 57 | 2017 |
| Neuropathogenesis of human immunodeficiency virus infection B Sillman, C Woldstad, J Mcmillan, HE Gendelman Handbook of clinical neurology 152, 21-40, 2018 | 48 | 2018 |
| Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir N Gautam, JEM McMillan, D Kumar, AN Bade, Q Pan, TA Kulkarni, W Li, ... Nature communications 12 (1), 3453, 2021 | 37 | 2021 |
| Pharmacokinetics of a long-acting nanoformulated dolutegravir prodrug in rhesus macaques JE McMillan, A Szlachetka, L Slack, B Sillman, B Lamberty, B Morsey, ... Antimicrobial agents and chemotherapy 62 (1), 10.1128/aac. 01316-17, 2018 | 37 | 2018 |
| Creation of a long-acting rilpivirine prodrug nanoformulation JR Hilaire, AN Bade, B Sillman, N Gautam, J Herskovitz, BLD Shetty, ... Journal of controlled release 311, 201-211, 2019 | 28 | 2019 |
| Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation S Deodhar, B Sillman, AN Bade, SN Avedissian, AT Podany, ... Nature communications 13 (1), 3226, 2022 | 21 | 2022 |
| CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice PK Dash, C Chen, R Kaminski, H Su, P Mancuso, B Sillman, C Zhang, ... Proceedings of the National Academy of Sciences 120 (19), e2217887120, 2023 | 13 | 2023 |
| Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice. Nat Commun 10: 2753 PK Dash, R Kaminski, R Bella, H Su, S Mathews, TM Ahooyi, C Chen, ... | 8 | 2019 |
| Recovery of latent HIV-1 from brain tissue by adoptive cell transfer in virally suppressed humanized mice H Su, S Sravanam, B Sillman, E Waight, E Makarov, S Mathews, ... Journal of Neuroimmune Pharmacology, 1-10, 2021 | 7 | 2021 |
| Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection MU Nayan, B Sillman, M Hasan, S Deodhar, S Das, A Sultana, NTH Le, ... Advanced Drug Delivery Reviews, 115009, 2023 | 5 | 2023 |
| Pathways for dolutegravir transformation from a daily oral to a once-a-year parenteral medicine S Deodhar, B Sillman, A Bade, JE McMillan, N Gautam, B Hanson, ... | 2 | 2022 |
| Long-acting dolutegravir formulations prevent neurodevelopmental impairments in a mouse model EG Foster, B Sillman, Y Liu, M Summerlin, V Kumar, BR Sajja, ... Frontiers in Pharmacology 14, 1294579, 2023 | 1 | 2023 |
| Polymer Delivery Systems for Long-Acting Antiretroviral Drugs MU Nayan, S Panja, A Sultana, LA Zaman, LK Vora, B Sillman, ... Pharmaceutics 16 (2), 183, 2024 | | 2024 |
| Challenges in ultralong-acting formulation development: eyes on buprenorphine S Deodhar, B Edagwa, B Sillman NeuroImmune Pharmacology and Therapeutics 2 (1), 1-3, 2023 | | 2023 |
| Development of a Long-Acting Nanoformulation of Dolutegravir for Prevention and Treatment of HIV-1 Infection B Sillman | | 2019 |
| Synthesis and Characterization of a Hydrophobic and Lipophilic Rilpivirine Prodrug Nanoparticle J Hilaire, B Sillman, A Bade, BLD Shetty, JE McMillan, B Edagwa, ... JOURNAL OF NEUROIMMUNE PHARMACOLOGY 13, S36-S36, 2018 | | 2018 |
